Brazil’s antitrust watchdog, Cade, has opened an ex officio preliminary proceeding involving pharmaceutical group EMS and executive Marcus Sanchez to examine a potential breach of competition rules. The trigger was an interview with Veja Negócios in which Sanchez said semaglutide pens are expensive to manufacture and that, despite the arrival of new competitors, prices were unlikely to “collapse.” At this stage, there is no allegation of wrongdoing: Cade is assessing whether there is enough evidence to warrant a deeper investigation.
At first glance, the comments may sound like little more than an explanation of the economics of the business. Injectable drugs carry manufacturing, regulatory and distribution costs, and companies naturally seek to explain why prices cannot fall indefinitely. For antitrust authorities, however, public statements about future pricing can take on a different significance when they are made in concentrated markets or at moments of rapid competitive change.
The logic is straightforward. Competition works best when each company has to work out for itself what its rivals are likely to do. The more predictable competitors’ pricing strategies become, the less uncertainty there is in the market. That does not mean an interview amounts to coordination, let alone a cartel. But it does explain why regulators pay attention to statements that might signal where an executive believes the market’s price floor lies.
The timing makes the episode particularly relevant. Brazil’s semaglutide market is entering a new phase, with more competition and expectations of lower prices. In that environment, comments about how far prices can fall are no longer merely a discussion about production costs. They can also shape expectations among manufacturers, investors and consumers about how the market is likely to behave.
Cade’s challenge will be to avoid confusing legitimate corporate communication with anticompetitive signaling. Executives need to be able to discuss costs, margins and industry dynamics. At the same time, regulators have good reason to scrutinize statements about future prices in concentrated markets. The EMS case may ultimately result in no finding of wrongdoing. But it already offers a useful reminder: in markets under scrutiny, talking about prices can itself come at a price.
Leave a Reply